Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AARD
AARD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AARD News
Aardvark Therapeutics Under Investigation for Securities Fraud
6d ago
Globenewswire
AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8
6d ago
moomoo
Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025
6d ago
NASDAQ.COM
Aardvark Therapeutics Q4 Earnings Beat Expectations
Mar 23 2026
seekingalpha
Investigation into Aardvark Therapeutics for Securities Fraud
Mar 17 2026
Globenewswire
Pomerantz Investigates Aardvark Therapeutics for Securities Fraud
Mar 12 2026
PRnewswire
Aardvark Therapeutics Under Investigation for Securities Fraud
Mar 10 2026
Globenewswire
Aardvark Therapeutics Faces Investigation After Trial Pause
Mar 04 2026
Globenewswire
Aardvark Pauses Phase 3 Trial, Stock Plunges 61%
Mar 04 2026
Benzinga
Aardvark Therapeutics Faces Securities Fraud Investigation
Mar 03 2026
Globenewswire
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 03 2026
Benzinga
U.S. Stocks Mixed Amid Iran-U.S. Conflict; Energy Shares Rise
Mar 02 2026
Benzinga
U.S. Stocks Open Lower; Energy Shares Rise Amid Mixed Economic Data
Mar 02 2026
Benzinga
Aardvark Pauses HERO Phase 3 Trial Amid Safety Concerns
Mar 02 2026
stocktwits
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 02 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 02 2026
Benzinga
Show More News
